Effects of buflomedil hydrochloride in occlusive arterial disease of the lower limbs stage IV.
Ten patients affected by occlusive arterial disease and presenting with skin lesions of the limbs were treated with buflomedil first i.v. and then orally, at a dosage of 600 mg/day. After a treatment period of 30 to 60 days, eight patients showed lesion regression with complete recovery; the remaining two patients dropped out of the study. The mechanism of action of buflomedil in healing skin lesions is also discussed.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D012883:Skin Ulcer / Q000188:drug therapy* / Q000209:etiology; D014665:Vasodilator Agents
D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil